Biocept Inc. buy stratec
Start price
26.03.19
/
50%
€300.36
Target price
04.11.21
€811.80
Performance (%)
-65.44%
End price
05.11.21
€103.80
Summary
This prediction ended on 05.11.21 with a price of €103.80. The BUY prediction by stratec for Biocept Inc. performed very badly with a performance of -65.44%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Biocept Inc. | - | - | - | - |
| iShares Core DAX® | 0.985% | 8.314% | 7.032% | 49.791% |
| iShares Nasdaq 100 | 2.067% | 16.765% | 35.952% | 96.632% |
| iShares Nikkei 225® | 2.270% | 15.605% | 46.568% | 69.047% |
| iShares S&P 500 | 1.043% | 11.077% | 26.456% | 68.087% |
Comments by stratec for this prediction
In the thread Biocept Inc. diskutieren
stratec stimmt dem Sentiment von 'Buy' zu
Biocept’s Target Selector is a liquid biopsy platform which, in addition to providing actionable data based on circulating tumor DNA (ctDNA) analysis, incorporates circulating tumor cell (NYSE:CTC) analysis which differentiates the company in an increasingly ‘crowded’ liquid biopsy space.”
In the thread Trading Biocept Inc.
Die von stratec gewählte maximale Laufzeit wurde überschritten